Case reports in endocrinology

One-Sided Graves' Disease Appearing During Tirzepatide Treatment in a Person with Diabetes

Updated

Abstract

Tirzepatide is associated with significant efficacy in lowering blood glucose levels and reducing body weight.

  • Tirzepatide acts as a dual agonist of the GIP and GLP-1 receptors.
  • Its increasing use is noted among patients with type 2 diabetes and obesity.
  • Gastrointestinal symptoms are commonly recognized adverse effects of tirzepatide.
  • Thyroid abnormalities are rare adverse effects linked to tirzepatide.
  • A rare case of unilateral Graves' disease developed during tirzepatide treatment.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free